Investor's Business Daily on MSN16d
Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...
Citigroup Cuts Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $26.00
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its price target trimmed by Citigroup from $27.00 to $26.00 in a ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Fmr LLC
Fmr LLC cut its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 10.9% in the third quarter, ...
Sarepta Therapeutics, Arrowhead Pharmaceuticals Ink Collaboration, Licensing Deal
Sarepta Therapeutics and Arrowhead Pharmaceuticals said they have entered a licensing and collaboration agreement worth more than $1 billion.
Yahoo Finance6d
Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) have lost 66%, as stock drops 9.3% this past week
With the stock having lost 9.3% in the past week, it's worth taking a look at business performance and seeing if there's any red flags. Arrowhead Pharmaceuticals wasn't profitable in the last twelve ...